LEVERKUSEN (dpa-AFX) - Bayer (BAYZF.PK, BAYRY.PK, BYR.L) said oncology is a key focus of the company's Pharma growth strategy, and it expects to be among top-10 players by 2030. The company noted that Nubeqa (Darolutamide) is a key cornerstone to grow its Oncology franchise short-to-mid term.
Bayer said the results of ARAMIS study already showed Nubeqa's strong clinical benefit for mid-stage prostate cancer patients. ARAMIS also revealed Darolutamide's positive tolerability profile.
Bayer stated that Darolutamide has the chance to become a foundational drug in prostate cancer - with peak sales potential lifted to above 3 billion euros. The company said it is committed to make Darolutamide available to a broad spectrum of prostate cancer patients.
Copyright(c) 2022 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX